Mink Therapeutics Inc (INKT) Stock Price, Quote & News

Company Profile

MiNK Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of allogeneic, off-the-shelf, and invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company develops agenT-797, an off-the-shelf, allogeneic, and native iNKT cell therapy that is in Phase 2 clinical trial for the clinical safety and efficacy of the combination of agenT-797, botensilimab plus balstilim...

Industry: Biotechnology

Sector: Healthcare

Phone: 212 994 8250

Website: minktherapeutics.com

Address:

149 Fifth Avenue, Suite 500, New York, United States

Dancady1 Sep. 8 at 7:54 PM

$INKT hope you bastards don’t get cheapies like I was buying

0 · Reply

enkemm Sep. 5 at 11:12 AM

$INKT INKT currently has a short interest of about 72,000 shares with a daily volume of perhaps 18,000 shares...1.4 days to average cover.

0 · Reply

2_logs_higher Sep. 4 at 6:12 PM

$AGEN $INKT Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor https://www.nature.com/articles/s41388-025-03491-0

0 · Reply

2_logs_higher Sep. 4 at 6:11 PM

$AGEN $INKT agenT-797: Allogeneic iNKT Cell Therapy for the Treatment of Cancer - Complete Clinical Response in a R/R Germ Cell Tumor https://cassyni.com/events/3HnQMhQThFaubXLYEWCuJm

1 · Reply

bluebush Sep. 4 at 5:15 PM

$INKT https://www.imperial.ac.uk/news/268073/modified-car-inkt-therapy-more-effective-childhood/

0 · Reply

Dancady1 Sep. 4 at 1:49 PM

$INKT I bought a useless meme coin for 6-7 months buying in the red and made money off it. You think I’m pulling out of a new cancer treatment company, that isn’t even worth 100 million. I’m thinking it’s worth 1-2 billion market cap and that is still smaller than Pepe market cap

0 · Reply

Dancady1 Sep. 4 at 1:46 PM

$INKT stop fighting start buying

0 · Reply

enkemm Sep. 2 at 6:07 PM

$INKT Neversurrender>>>>>I am at a loss as to why you harbor so much rage against Dr. Garo Armen. Did he poison your dog? Perhaps he kidnapped your daughter? Did he sneak into you home and steal all your wife's jewelry, or even worse, did he announce on a public address system that your mother wears bloomers? How do you figure that AGEN diluting their stock by 2.5% (800,000 shares with 32 million outstanding) equals INKT getting crushed? I honestly cannot follow this drivel. AGEN's biggest asset is its 48% interest in INKT. Dr. Armen could have sold AGEN's 2 million shares in INKT at 28.00/share and pocketed a cool 50 to 60 million if he was the swindler you make him out to be. Instead he sold roughly 500,000 shares at 28.00/share causing minimal dilution and a fiscal roadway to mid 2026. Dr. Armen formed his company some 31 years ago, which makes your allegations even less credible. Remember...you do not want to go through life hostile and stupid...that is no way to live.

1 · Reply

neversurrender2024 Aug. 30 at 2:15 AM

$INKT agen just filed plans to sell 800k shares....are you ready to get crushed?

0 · Reply

Dancady1 Aug. 29 at 6:26 PM

$INKT pos

0 · Reply

MiNK Therapeutics, Inc. (INKT) Q2 2025 Earnings Call Transcript

Aug 14, 2025, 7:30 AM EDT - 26 days ago

MiNK Therapeutics Reports Clinical and Strategic Milestones and Second Quarter 2025 Results

Jul 31, 2025, 8:30 AM EDT - 5 weeks ago

MiNK Therapeutics to Provide Corporate Update and First Quarter 2025 Financial Report

Jul 15, 2025, 8:21 AM EDT - 2 months ago

MiNK Therapeutics Announces Frontiers in Immunology Publication Highlighting iNKT Cells as a Dual-Function Platform Key to Overcoming Barriers in Solid Tumor Cell Therapy

Jul 11, 2025, 12:33 PM EDT - 2 months ago

Why Is Nano-Cap MiNK Therapeutics Stock Gaining Over 400% On Friday?

Jun 10, 2025, 1:33 PM EDT - 3 months ago

MiNK Therapeutics Announces Virtual Annual Shareholders Meeting

Jun 2, 2025, 9:29 AM EDT - 3 months ago

MiNK Therapeutics Awarded Prestigious NIAID Grant to Advance Allo-iNKT Cell Therapy for Prevention of GvHD in Stem Cell Transplant Patients

May 15, 2025, 1:21 PM EDT - 4 months ago

MiNK Therapeutics, Inc. (INKT) Q1 2025 Earnings Call Transcript

May 15, 2025, 7:30 AM EDT - 4 months ago

MiNK Therapeutics Reports Q1 2025 Results and Highlights Clinical & Strategic Progress

Mar 18, 2025, 11:28 AM EDT - 6 months ago

MiNK Therapeutics, Inc. (INKT) Q4 2024 Earnings Call Transcript

Mar 18, 2025, 7:30 AM EDT - 6 months ago

MiNK Therapeutics Reports Fourth Quarter & Full Year 2024 Results and Highlights Business Progress

Mar 4, 2025, 7:30 AM EST - 6 months ago

MiNK Therapeutics to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report

Feb 24, 2025, 8:30 AM EST - 7 months ago

MiNK Therapeutics Presents First-in-Kind Allo-iNKTs Combination Data in 2L Gastric Cancer at AACR IO Annual Meeting

Feb 12, 2025, 1:00 PM EST - 7 months ago

MiNK Therapeutics to Present Updated Data from Phase 2 Study Testing AgenT-797 in Gastric Cancer at AACR IO Annual Meeting

Jan 23, 2025, 2:13 PM EST - 8 months ago

MiNK Therapeutics Targets Immune Reconstitution to Combat Advanced Gastroesophageal Cancers with Novel Combination of Allo-iNKTs plus BOT/BAL at ASCO GI

Dec 18, 2024, 9:45 AM EST - 9 months ago

MiNK Therapeutics to Present iNKT Cell Therapy in Gastric Cancer at ASCO GI Annual Meeting

Nov 14, 2024, 10:47 AM EST - 10 months ago

MiNK Therapeutics, Inc. (INKT) Q3 2024 Earnings Conference Call Transcript

Nov 11, 2024, 7:30 AM EST - 10 months ago

MiNK Therapeutics to Provide Corporate Update and Third Quarter 2024 Financial Report

Nov 7, 2024, 10:00 AM EST - 10 months ago

MiNK's iNKT Cell Therapy Shows Potential for Optimal Multi-Combination for Resistant Solid Cancers at SITC 2024

Oct 31, 2024, 9:15 AM EDT - 11 months ago

MiNK Therapeutics Announces Appointment of Dr. Robert Kadlec to Board of Directors

Oct 8, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics and Autonomous Therapeutics Announce Collaboration to Develop Novel Therapies Targeting Metastatic Tumors

Oct 4, 2024, 9:10 AM EDT - 1 year ago

MiNK Therapeutics to Present Data From iNKT Cell Programs at SITC 2024

Sep 3, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Aug 13, 2024, 2:51 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q2 2024 Earnings Call Transcript

Aug 13, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Second Quarter 2024 Results and Business Update

Aug 1, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics to Provide Corporate Update and Second Quarter 2024 Financial Report

Jul 31, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Regains Compliance with Nasdaq Capital Market Requirement

May 22, 2024, 7:30 AM EDT - 1 year ago

MiNK Presents AgenT-797 Clinical Activity in Immune-Compromised Transplant Patient with Severe ARDS at ATS Annual Meeting

May 14, 2024, 11:07 AM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q1 2024 Earnings Call Transcript

May 14, 2024, 7:30 AM EDT - 1 year ago

MiNK Reports First Quarter 2024 Results

May 13, 2024, 7:30 AM EDT - 1 year ago

MiNK Therapeutics Announces $5.8 Million Private Placement and Appointment of Board Observer

Apr 30, 2024, 7:30 AM EDT - 1 year ago

MiNK to Provide Corporate Update and First Quarter 2024 Financial Report

Apr 8, 2024, 12:00 PM EDT - 1 year ago

MiNK Therapeutics Announces Promising Preclinical Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR

Mar 21, 2024, 2:20 PM EDT - 1 year ago

MiNK Therapeutics, Inc. (INKT) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 7:00 AM EDT - 1 year ago

MiNK Reports Fourth Quarter and Year-End 2023 Results

Mar 7, 2024, 7:30 AM EST - 1 year ago

MiNK to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial Report

Mar 6, 2024, 8:30 AM EST - 1 year ago

MiNK Announces Preclinical Data Showcasing Activity of MiNK-215 Against Colorectal Cancer Liver Metastases at AACR 2024

$MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene$

Jan 30, 2024, 8:00 AM EST - 1 year ago

MiNK's AgenT-797 Offers New Hope in Overcoming ICI Resistance in PD-1 Refractory Gastric Cancer - Published in Oncogene

Dec 20, 2023, 7:30 AM EST - 1 year ago

ImmunoScape and MiNK Therapeutics Collaborate to Accelerate Novel TCR Identification and Therapeutic Development

Nov 9, 2023, 7:00 AM EST - 1 year ago

MiNK Therapeutics Reports Third Quarter 2023 Results

Nov 3, 2023, 12:00 PM EDT - 2 years ago

MiNK Therapeutics Presents Clinical Activity and Long-Term Persistence of Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Oct 30, 2023, 8:00 AM EDT - 2 years ago

MiNK to Provide Third Quarter 2023 Financial Report and Corporate Update

Sep 27, 2023, 9:05 AM EDT - 2 years ago

MiNK Therapeutics To Present Data Update From Allogeneic iNKT Cells in Solid Tumors at SITC 2023

Aug 24, 2023, 8:30 AM EDT - 2 years ago

MiNK Therapeutics to Participate in September Investor Conferences

Aug 10, 2023, 7:30 AM EDT - 2 years ago

MiNK Therapeutics Reports Second Quarter 2023 Results

Jul 28, 2023, 8:30 AM EDT - 2 years ago

MiNK to Provide Second Quarter 2023 Financial Report and Corporate Update

May 22, 2023, 8:30 AM EDT - 2 years ago

MiNK Presents Clinical Data on Allogeneic iNKT Cells (agenT-797) in Severe Respiratory Distress at the American Thoracic Society International Conference

May 18, 2023, 8:30 AM EDT - 2 years ago

MiNK's Novel FAP-CAR-iNKT Presented at ASGCT

May 14, 2023, 2:25 PM EDT - 2 years ago

MiNK Therapeutics, Inc. (INKT) Q1 2023 Earnings Call Transcript

May 11, 2023, 8:00 AM EDT - 2 years ago

MiNK Therapeutics Reports Corporate Update and First Quarter 2023 Financial Results

Dancady1 Sep. 8 at 7:54 PM

$INKT hope you bastards don’t get cheapies like I was buying

0 · Reply

enkemm Sep. 5 at 11:12 AM

$INKT INKT currently has a short interest of about 72,000 shares with a daily volume of perhaps 18,000 shares...1.4 days to average cover.

0 · Reply

2_logs_higher Sep. 4 at 6:12 PM

$AGEN $INKT Salvage therapy with allogeneic invariant natural killer cells in a heavily pre-treated germ cell tumor https://www.nature.com/articles/s41388-025-03491-0

0 · Reply

2_logs_higher Sep. 4 at 6:11 PM

$AGEN $INKT agenT-797: Allogeneic iNKT Cell Therapy for the Treatment of Cancer - Complete Clinical Response in a R/R Germ Cell Tumor https://cassyni.com/events/3HnQMhQThFaubXLYEWCuJm

1 · Reply

bluebush Sep. 4 at 5:15 PM

$INKT https://www.imperial.ac.uk/news/268073/modified-car-inkt-therapy-more-effective-childhood/

0 · Reply

Dancady1 Sep. 4 at 1:49 PM

0 · Reply

Dancady1 Sep. 4 at 1:46 PM

$INKT stop fighting start buying

0 · Reply

enkemm Sep. 2 at 6:07 PM

1 · Reply

neversurrender2024 Aug. 30 at 2:15 AM

$INKT agen just filed plans to sell 800k shares....are you ready to get crushed?

0 · Reply

Dancady1 Aug. 29 at 6:26 PM

$INKT pos

0 · Reply

None_ Aug. 27 at 10:01 PM

$INKT $AGEN https://acir.org/weekly-digests/2025/august/agonist-anti-cd40-shows-promise-in-a-phase-1-clinical-trial

1 · Reply

neversurrender2024 Aug. 27 at 9:05 PM

$AGEN down to 48% ownership of $INKT

0 · Reply

Amarin2020 Aug. 27 at 7:29 PM

$INKT Squeeze slow $30

0 · Reply

ShaoMin24 Aug. 27 at 7:25 PM

$INKT

0 · Reply

kellyc09 Aug. 27 at 7:24 PM

$INKT Wish I knew why but will take it.

0 · Reply

roguesama Aug. 27 at 7:24 PM

$INKT

0 · Reply

LongLane Aug. 27 at 9:50 AM

$INKT volume picking up, potential early sign of a breakout.

0 · Reply

Dancady1 Aug. 25 at 8:46 PM

$INKT who is still here

0 · Reply

Dgun Aug. 25 at 6:58 PM

$INKT daily bollinger- not quite, literally

0 · Reply

enkemm Aug. 25 at 3:00 PM

$INKT So..."Through August 21, 2025, we have offered and sold 478,462 shares of common stock for gross proceeds of $13,414,485 pursuant to the Agreement. Accordingly, because we are no longer subject to the sales limitations of such General Instruction I.B.6, we may offer and sell up to an additional $36,585,515 of shares of common stock pursuant to the Agreement." Accordingly, it seems the company obtained about $28.00/share, and given their runway now goes to mid 2026 with anticipated catalysts at the end of the year...I am going to play mother hen...and sit on my eggs.

0 · Reply

enkemm Aug. 22 at 12:40 PM

$INKT I find the sewage sucking comments of Neversurrender2024 completely inane. Neversurrnder is soooooooooo short he/she needs a parachute to jump off a dime. In attempting to put together known information, it appears from the quarterly earnings call that the company raised 13,000,000 through sale of common stock. This extended the cash runway to mid 2026. It also appears that the shares sold numbered 500,000, bringing the sale price to $26/share. So why would investors worry about an ATM, further dilution, or that the share price is going to crash. Neversurrender appears to be a short, reverse pumper. Hey Never.....there are less than 180,000 shares short at this point. Are you going to be one of the shorts to get juiced instead of gettin out while the gettin is good?

0 · Reply

Dgun Aug. 21 at 7:36 PM

$INKT calm before the storm! scary:S

0 · Reply

Market Cap	66.94M
Revenue (ttm)	0.00
Net Income (ttm)	-9.51M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	69,400
Avg Vol	1,252,792
Day's Range	N/A - N/A
Shares Out	4.52M
Stochastic %K	85%
Beta	0.33
Analysts	Sell
Price Target	$39.00